Search results for "Stability."

showing 10 items of 3015 documents

Robust stabilisation of 2D state-delayed stochastic systems with randomly occurring uncertainties and nonlinearities

2013

This paper is concerned with the state feedback control problem for a class of two-dimensional (2D) discrete-time stochastic systems with time-delays, randomly occurring uncertainties and nonlinearities. Both the sector-like nonlinearities and the norm-bounded uncertainties enter into the system in random ways, and such randomly occurring uncertainties and nonlinearities obey certain mutually uncorrelated Bernoulli random binary distribution laws. Sufficient computationally tractable linear matrix inequality–based conditions are established for the 2D nonlinear stochastic time-delay systems to be asymptotically stable in the mean-square sense, and then the explicit expression of the desired…

Distribution (number theory)Linear matrix inequality (LMI)Linear matrix inequality2D stochastic systems; Linear matrix inequality (LMI); Randomly occurring nonlinearities; Randomly occurring uncertainties; Control and Systems Engineering; Theoretical Computer Science; Computer Science Applications1707 Computer Vision and Pattern RecognitionBinary numberComputer Science Applications1707 Computer Vision and Pattern RecognitionExpression (computer science)Randomly occurring nonlinearitiesComputer Science ApplicationsTheoretical Computer ScienceNonlinear systemBernoulli's principleControl and Systems EngineeringControl theoryStability theory2D stochastic systemsRandomly occurring uncertaintiesMathematicsInternational Journal of Systems Science
researchProduct

Networks of Manufacturers and Retailers

2005

We study the endogenous formation of networks between manufacturers of differentiated goods and multi-product retailers who interact in a successive duopoly. Joint consent is needed to establish and/or maintain a costly link between a manufacturer and a retailer. We find that only three distribution networks are stable for particular values of the degree of product differentiation and link costs: (i) the non-exclusive distribution and non-exclusive dealing network in which both retailers distribute both products is stable for intermediate degree of product differentiation and small link costs; (ii) the exclusive distribution and exclusive dealing network in which each retailer distributes a…

Distribution networksbusiness.industryDistribution (economics)Exclusive dealingSocial WelfareProduct differentiationBusinessProduct (category theory)Stability (probability)DuopolyIndustrial organizationSSRN Electronic Journal
researchProduct

Die Primärstabilität von manuell und roboterassistiert implantierten Hüftendoprothesenstielen: eine biomechanische Untersuchung an Kunstfemora

2004

AIM We investigated the initial stability of cementless stems implanted with robotic milling and conventional manual broaching. METHODS Proximally porous structured stems (G2, ESKA-Implants, Luebeck, Germany) were implanted into synthetic femora. In one group, the femoral cavity was prepared by a CT-based robot (CASPAR, URS-Ortho, Germany) with a high-speed milling head. In the other group, femora were rasped manually with broaches. The broaches had 1 mm proximal press-fit, the robotic cavities 1.5 mm. The implants were exposed to 15 000 loading cycles with 1 000 +/- 500 N. The direction of forces on the implant head were chosen to simulate stair climbing. Internal rotation and translation …

Dorsummedicine.medical_specialtyMaterials scienceStair climbingOperating proceduresInternal rotationtechnology industry and agricultureInitial stabilityBroachingSurgerymedicineOrthopedics and Sports MedicineSurgeryFemurImplantBiomedical engineeringZeitschrift für Orthopädie und ihre Grenzgebiete
researchProduct

On the stability of the collocation method for the double layer operator on polyhedral domains in R3

2002

Double layer (biology)Operator (physics)Collocation methodMathematical analysisStability (learning theory)MathematicsPAMM
researchProduct

New binary solid dispersion of indomethacin with surfactant polymer: From physical characterization to in vitro dissolution enhancement

2009

This article investigated preparation of solid dispersions containing a poor water-soluble drug, indomethacin (IND), and a new surfactant polymer, polyoxyethylene 32 distearate (POED). Solid dispersions were prepared by the melting method and characterized by DSC, hot-stage microscopy (HSM), X-ray diffraction (XRD) and scanning electron microscopy (SEM). DSC and HSM analyses performed on IND/POED physical mixtures indicated that IND could dissolve in liquid POED. The materials showed complete miscibility at liquid state. Combination of DSC, XRD, and SEM revealed that these materials had limited miscibility at the solid state. Up to 20% w/w IND in POED, we did not detect significant modifica…

Drug CarriersRecrystallization (geology)PolymersChemistryDrug CompoundingDrug StorageIndomethacinPharmaceutical ScienceMiscibilityPolyethylene GlycolsSurface-Active AgentsDifferential scanning calorimetryDrug StabilitySolubilityPulmonary surfactantChemical engineeringOrganic chemistryCrystalliteSolubilityCrystallizationDissolutionSolid solutionJournal of Pharmaceutical Sciences
researchProduct

Loading, release and stability of epirubicin-loaded drug-eluting beads.

2015

Purpose The aim of this study was to determine the loading efficiency, physico-chemical stability and release of epirubicin-loaded DC Bead™ (Biocompatibles UK Ltd, a BTG International group company) (bead size 70–150 µm (=DC Bead M1™) and 100–300 µm) after loading with epirubicin solution (2 mg/ml) or reconstituted powder formulation (25 mg/ml) and controlled storage. Methods DC Bead™ were loaded with 76 mg epirubicin solution (Epimedac™, Medac GmbH) or 75 mg epirubicin powder formulation (Farmorubicin™, Pharmacia Pfizer GmbH) per 2 ml of beads. Drug loading efficiency and stability were determined by measuring the epirubicin concentration in the excess solution after predetermined interval…

Drug CompoundingDrug StorageBead030218 nuclear medicine & medical imaging03 medical and health sciences0302 clinical medicineDrug StabilitymedicinePharmacology (medical)Particle SizeChromatography High Pressure LiquidEpirubicinDrug CarriersChromatographyAntibiotics AntineoplasticDrug eluting beadsElutionbusiness.industrySyringesMicrospheresOncology030220 oncology & carcinogenesisvisual_artDrug releasevisual_art.visual_art_mediumPowdersbusinessEpirubicinmedicine.drugJournal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners
researchProduct

Stability of tacrolimus ophthalmic solution

2017

Purpose The stability of 0.3-mg/mL tacrolimus ophthalmic solution at different storage temperatures was studied. Methods A sterile ophthalmic solution of 0.3 mg/mL tacrolimus was prepared in triplicate under aseptic conditions by diluting tacrolimus in eye drops. Three aliquots of this solution were transferred into polypropylene bottles and stored at 25, 2–8, or −15 to −25 °C. Samples were collected immediately after preparation and at selected time points and assayed in triplicate using high-performance liquid chromatography (HPLC). Samples were also visually examined for macroscopic changes. The 0.3-mg/mL tacrolimus solution was also exposed to acidic treatment and heat to force its degr…

Drug Storagemedicine.medical_treatmentAdministration Ophthalmicchemical and pharmacologic phenomena030226 pharmacology & pharmacyHigh-performance liquid chromatographyTacrolimus03 medical and health sciences0302 clinical medicineDrug StabilitymedicineHumansChromatography High Pressure LiquidPharmacologyChromatographyChemistryHealth PolicyTemperatureEye dropTacrolimusPharmaceutical Solutionssurgical procedures operativeOphthalmic solutionsAnesthesia030221 ophthalmology & optometryAseptic processingOphthalmic SolutionsImmunosuppressive AgentsAmerican Journal of Health-System Pharmacy
researchProduct

Biowaiver Monographs for Immediate-Release Solid Oral Dosage Forms: Enalapril

2018

Literature data relevant to the decision to allow a waiver of in vivo bioequivalence testing for the marketing authorization of immediate-release, solid oral dosage forms containing enalapril maleate are reviewed. Enalapril, a prodrug, is hydrolyzed by carboxylesterases to the active angiotensin-converting enzyme inhibitor enalaprilat. Enalapril as the maleate salt is shown to be highly soluble, but only 60%-70% of an orally administered dose of enalapril is absorbed from the gastrointestinal tract into the enterocytes. Consequently, enalapril maleate is a Biopharmaceutics Classification System class III substance. Because in situ conversion of the maleate salt to the sodium salt is sometim…

DrugEnalaprilatmedia_common.quotation_subjectAdministration OralPharmaceutical ScienceAngiotensin-Converting Enzyme InhibitorsBioequivalencePharmacology030226 pharmacology & pharmacyPermeabilityDosage form03 medical and health sciences0302 clinical medicineDrug StabilityEnalaprilmedicineHumansProdrugsEnalaprilmedia_commonChromatographyChemistryProdrugBiopharmaceutics Classification SystemIntestinal AbsorptionSolubilityTherapeutic EquivalencyEnalapril Maleate030220 oncology & carcinogenesisTabletsmedicine.drugJournal of Pharmaceutical Sciences
researchProduct

Potential transbuccal delivery of l-DOPA methylester prodrug: stability in the environment of the oral cavity and ability to cross the mucosal tissue

2016

Levodopa (l-DOPA) is the most effective pharmacologic agent in Parkinson's disease and remains the "gold standard". Nevertheless, in long-term treatments, dyskinesias and motor complications can emerge. In this work, the combined use of l-DOPA methylester hydrochloride prodrug (LDME) with transbuccal drug delivery was supposed as a good alternative method to optimize the bioavailability of l-DOPA, to maintain constant plasma levels and to decrease the drug unwanted effects. The effects of environmental pH on buccal delivery of LDME were evaluated ex vivo. The increase of pH value from 5.8 to 6.2 implies an improvement of drug permeation. Since the pH increase causes the raising of hydrolyti…

DrugHydrochloridemedia_common.quotation_subjectPharmaceutical Science02 engineering and technologyPharmacologyAntiparkinson AgentsLevodopachemical stability03 medical and health scienceschemistry.chemical_compoundDrug Delivery Systems0302 clinical medicineDrug StabilitySettore MED/28 - Malattie OdontostomatologicheProdrugsmedia_commonBuccal permeationMouthintellidrug deviceMouth MucosaParkinson DiseaseGeneral MedicineBuccal administrationPermeationProdrug021001 nanoscience & nanotechnologytransmucosal drug deliveryBioavailabilitychemistrySettore CHIM/09 - Farmaceutico Tecnologico ApplicativoDrug deliveryprodrug0210 nano-technology030217 neurology & neurosurgeryEx vivo
researchProduct

Solid lipid nanoparticles containing tamoxifen characterization and in vitro antitumoral activity.

2005

Solid lipid nanoparticles (SLNs) containing tamoxifen, a nons- teroidal antiestrogen used in breast cancer therapy, were prepared by microemulsion and precipitation techniques. Tamoxifen loaded SLNs seem to have dimensional properties useful for parenteral administration, and in vitro plasmatic drug release studies demon- strated that these systems are able to give a prolonged release of the drug in the intact form. Preliminary study of antiproliferative ac- tivity in vitro, carried out on MCF-7 cell line (human breast cancer cells), demonstrated that SLNs, containing tamoxifen showed an antitumoral activity comparable to free drug. The results of char- acterization studies and of in vitro …

DrugOctanolsMaterials scienceTime FactorsAntineoplastic Agents Hormonalmedia_common.quotation_subjectPharmaceutical SciencePharmacologyColloidal Drug Delivery Systems Solid Lipid Nanoparticles (SLNs) TamoxifenBreast cancerDrug StabilityCell Line TumorSolid lipid nanoparticlemedicineHumansParticle Sizeskin and connective tissue diseasesmedia_commonCell ProliferationDrug CarriersWaterGeneral MedicineHydrogen-Ion Concentrationmedicine.diseaseAntiestrogenLipidsIn vitroNanostructuresbody regionsTamoxifenSolubilityDelayed-Action PreparationsCancer cellDrug carrierTamoxifenmedicine.drugDrug delivery
researchProduct